Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 5/20 | 0.54 |
| ▸ | BACE1 | P56817 | 3/20 | 0.51 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.49 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.48 |
| ▸ | VIPR2 | P41587 | 4/20 | 0.48 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678306 | 0.93 | KISS1R (0.56) | KISS1RBACE1VIPR1BACE2VIPR2 | |
| SCHEMBL31690550 | 0.92 | KISS1R (0.56) | KISS1RBACE1VIPR1BACE2VIPR2 | |
| SCHEMBL31690551 | 0.92 | KISS1R (0.56) | KISS1RBACE1VIPR1BACE2VIPR2 | |
| SCHEMBL30184172 | 0.90 | KISS1R (0.53) | KISS1RBACE1VIPR1BACE2VIPR2 | |
| SCHEMBL30184408 | 0.90 | BACE1 (0.56) | KISS1RBACE1VIPR1BACE2 | |
| SCHEMBL29907889 | 0.90 | VIPR1 (0.53) | KISS1RBACE1VIPR1BACE2VIPR2 | |
| SCHEMBL30752382 | 0.90 | VIPR1 (0.53) | KISS1RBACE1VIPR1BACE2VIPR2 | |
| SCHEMBL29353346 | 0.90 | VIPR1 (0.53) | KISS1RBACE1VIPR1BACE2VIPR2 | |
| SCHEMBL30865079 | 0.89 | BACE1 (0.58) | KISS1RBACE1BACE2 | |
| SCHEMBL31622476 | 0.89 | VIPR1 (0.55) | KISS1RBACE1VIPR1BACE2VIPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218041-A1 | MOLECULAR DESIGN OF GLUCOSE SENSORS IN GLUCOSE-RESPONSIVE INSULIN ANALOGUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-04 | — | — | US | disclosed |
| EP-4334338-A1 | MOLECULAR DESIGN OF GLUCOSE SENSORS IN GLUCOSE-RESPONSIVE INSULIN ANALOGUES | The Trustees of Indiana University (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022235691-A1 | MOLECULAR DESIGN OF GLUCOSE SENSORS IN GLUCOSE-RESPONSIVE INSULIN ANALOGUES | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-4003426-A1 | INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH | Thermalin Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218041-A1 | MOLECULAR DESIGN OF GLUCOSE SENSORS IN GLUCOSE-RESPONSIVE INSULIN ANALOGUES | IAPP, GPR119, INSR | KISS1R 1560/4885BACE1 1908/4885VIPR1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.